PARP1 and ovarian cancer: Fong et al have has first demonstrated the activity of single agent PARP inhibitor olaparib in BRCA-deficient advanced ovarian, breast and prostate cancers [43], with grater activity observed in platinum sensitive ovarian cancer patients [44].